Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

Author(s): Akihito Kawazoe, MD¹; Rui-Hua Xu, MD, PhD²; Pilar García-Alfonso, MD³; Maria Passhak, MD⁴; Hao-Wei Teng, MD, PhD^5,6; Ardaman Shergill, MD⁷; Mahmut Gumus, MD⁸; Camilla Qvortrup, MD, PhD⁹; Sebastian Stintzing, MD¹⁰; Kathryn Towns, MD¹¹; Tae Won Kim, MD¹²; Kai Keen Shiu, MD, PhD¹³; Juan Cundom, MD¹⁴; Sumitra Ananda, MD¹⁵; Andrey Lebedinets, MD¹⁶; Rong Fu, PhD¹⁷; Rishi Jain, MD¹⁸; David Adelberg, MD¹⁸; Volker Heinemann, MD, PhD¹⁹; Takayuki Yoshino, MD, PhD¹; Elena Elez, MD, PhD²⁰

Source: https://doi.org/10.1200/JCO.23.02736

Dr. Maen Hussein's Thoughts

Overall survival (OS) improvement was not statistically significant in the study arm but is a non-chemotherapy option. Patients here had tumors with MSS.

PURPOSE

Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination with pembrolizumab improves outcomes compared with standard of care (SOC) in previously treated mismatch repair proficient or not microsatellite instability high (pMMR or not MSI-H) mCRC.

METHODS

In this international, multicenter, randomized, controlled, open-label, phase III study, eligible patients age 18 years and older with unresectable, pMMR or not MSI-H mCRC, that had progressed on or after, or could not tolerate, standard treatment, were randomly assigned 1:1 to lenvatinib 20 mg orally once daily plus pembrolizumab 400 mg intravenously once every 6 weeks or investigator’s choice of regorafenib or trifluridine/tipiracil (SOC). Randomization was stratified by presence or absence of liver metastases. The primary end point was overall survival (OS). LEAP-017 is registered at ClinicalTrials.gov (NCT04776148), and has completed recruitment.

RESULTS

Between April 8, 2021, and December 21, 2021, 480 patients were randomly assigned to lenvatinib plus pembrolizumab (n = 241) or SOC (n = 239). At final analysis (median follow-up of 18.6 months [IQR, 3.9]), median OS with lenvatinib plus pembrolizumab versus SOC was 9.8 versus 9.3 months (hazard ratio [HR], 0.83 [95% CI, 0.68 to 1.02]; P = .0379; prespecified threshold P = .0214). Grade ≥3 treatment-related adverse events occurred in 58.4% (lenvatinib plus pembrolizumab) versus 42.1% (SOC) of patients. Two participants died due to treatment-related adverse events, both in the lenvatinib plus pembrolizumab arm.

CONCLUSION

In patients with pMMR or not MSI-H mCRC that had progressed on previous therapy, there was no statistically significant improvement in OS after lenvatinib plus pembrolizumab treatment versus SOC. No new safety signals were observed.

Author Affiliations

¹National Cancer Center Hospital East, Kashiwa, Japan; ²Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangdong, China; ³Medical Oncology Service, Hospital G. U. Gregorio Marañón, IiSGM, Universidad Complutense, Madrid, Spain; ⁴Rambam Health Care Campus-Oncology, Haifa, Israel; ⁵Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; ⁶National Yang Ming Chiao Tung University, Hsinchu, Taiwan; ⁷University of Chicago Pritzker School of Medicine, Chicago, IL; ⁸Istanbul Medeniyet University Hospital, Istanbul, Turkey; ⁹Righospitalet, Copenhagen, Denmark; ¹⁰Department of Oncology, Rigshospitalet, Copenhagen, Denmark; ¹¹North York General Hospital, Toronto, ON, Canada; ¹²Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea; ¹³University College Hospital, NHS Foundation Trust, London, United Kingdom; ¹⁴Instituto de Diagnóstico e Investigaciones Metabólicas, Buenos Aires, Argentina; ¹⁵Peter MacCallum Cancer Centre and Epworth Healthcare, Melbourne, VIC, Australia; ¹⁶Leningrad Regional Clinical Oncology Dispensary, St Petersburg, Russia; ¹⁷MSD China, Shanghai, China; ¹⁸Merck & Co, Inc, Rahway, NJ; ¹⁹Comprehensive Cancer Center at Ludwig Maximilian University of Munich, Munich, Germany; ²⁰Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Here is a large phase-III well done study confirming what we knew from earlier studies, that ipilimumab plus nivolumab (Ipi+Nivo) is highly active and effective in the microsatellite instability-high metastatic colorectal cancer (MSI-high met-CRC) population. This is most likely more effective than single agent IO therapy but with higher rates of toxicity. When all things are equal, I would consider this to be the standard of care (SOC) in this context.

Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)

This Japanese study showed no benefit with the addition of oxaliplatin to fluoropyrimidine plus bevacizumab (5FU+bev) in patients who were aged 70-74 but unfit, or >=75. Interestingly survival was actually shorter in the patients who received oxaliplatin at 21.3 vs 19.7 months.

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study

Less maintenance is NOT NON-inferior, so it is inferior in patients with wild type BRAF metastatic colon cancer. So it is better to keep on the full regimen. Although, quality of life is better.

A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening

Colorectal cancer screening by peripheral blood testing? This cell-free DNA assay had an 83% sensitivity and 90% specificity for advanced neoplasia. However, the issue is that this does not detect precancerous lesions well. Colonoscopy has its obvious advantages as it can both diagnose colorectal cancer as well as eradicate precancerous lesions.

MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial

This is a nice, practical study showing that when considering liver directed therapy, options in metastatic CRC, CT’s alone are insufficient and contrasted MRI can be helpful. More than 30% of patients had care that was impacted using MRI prior to any therapeutic decisions.